Befiradol is under clinical development by Neurolixis and currently in Phase II for Drug-Induced Dyskinesia. According to GlobalData, Phase II drugs for Drug-Induced Dyskinesia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Befiradol LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Befiradol (NLX-112, F-13640) is under development for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease, acute pain, tonic pain and depression. It is administered through oral route. It is a new chemical entity (NCE). The drug candidate acts by targeting serotonin 5-HT (1A) receptor. It was also under development for moderate to severe central neuropathic pain, diabetic neuropathic pain and cancer pain.
Neurolixis is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. Its pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induced dyskinesia; and NLX-101 is a drug used for the treatment of breathing difficulties in Rett’s syndrome, a genetically-encoded orphan disorder. Neurolixis therapeutic focus include pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. The company offers treatment solutions for human central nervous system disorders such as Parkinson’s disease, Rett syndrome, depression and schizophrenia. Neurolixis is headquartered in Dana Point, California, the US.
For a complete picture of Befiradol’s drug-specific PTSR and LoA scores, buy the report here.